$83.84 meals Payment -- Merck & Co to Dr. Brian Wright

Merck & Co. provided an $83.84 meal payment to an Infectious Disease physician in NY.

This page provides a detailed analysis of a $83.84 meals payment from Merck & Co to Dr. Brian Wright. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$83.84
Payment Typemeals
Payment NatureFood and Beverage
Pharmaceutical CompanyMerck & Co
PhysicianDr. Brian Wright
NPI Number1870440000
Physician SpecialtyInfectious Disease
LocationRochester, NY
Date of Payment2026-03-03
Related Drug/DeviceStelara
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Merck & Co made a $83.84 meals payment to Brian Wright, a Infectious Disease specialist in Rochester, NY. The payment was associated with Stelara. This record details a $83.84 payment from Merck & Co. to Dr. Brian Wright for "Food and Beverage" related to the drug Stelara. The payment occurred on March 3, 2026, and was categorized as a "meal". Dr. Wright's specialty is Infectious Disease, and the payment was made in Rochester, NY.

Patient Guidance: What This Payment Means for You

This payment was for a meal provided by a pharmaceutical company. It is important to understand the nature of any payments received from drug manufacturers. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Meals provided by pharmaceutical companies to physicians are common, especially for educational purposes or to discuss specific drugs. The amount of $83.84 is generally considered low in the context of physician-industry interactions.

Regulatory Context: Sunshine Act Requirements

Payments from pharmaceutical companies to healthcare providers are subject to disclosure under the Sunshine Act (part of the Affordable Care Act) to promote transparency in the healthcare industry.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding meals Payments

Food and beverage payments cover meals provided to physicians during pharmaceutical sales representative visits, medical conferences, and educational events. While individual meal payments tend to be small (often under $100), research published in JAMA Internal Medicine has shown that even modest meals can be associated with changes in prescribing behavior. Meal payments are the most common type of pharmaceutical payment to physicians.

Frequently Asked Questions About This Payment

What was this $83.84 payment for?

This was a meals payment of $83.84 from Merck & Co to Brian Wright, categorized as "Food and Beverage". It was associated with Stelara. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Brian Wright accept pharmaceutical money?

Yes, Brian Wright received this $83.84 payment from Merck & Co. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Brian Wright's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this meals payment?

A meals payment of $83.84 is generally routine and common in the industry. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Infectious Disease?

To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Brian Wright's relationship with Merck & Co?

The payment amount is relatively small, suggesting it was for a single meal or a small group. This $83.84 meals payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Infectious Disease?

The payment is directly linked to a specific drug, Stelara, which is used to treat various inflammatory conditions.

What should patients do after learning about this payment?

This payment was for a meal provided by a pharmaceutical company. It is important to understand the nature of any payments received from drug manufacturers.

What else should I know about this meals payment?

The date of payment is in the future (2026), which may indicate a scheduled or anticipated expense.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.